Date Document
31/12/2020 Secondary Trading Notice & Appendix 2A
29/12/2020 Secondary Trading Notice & Appendix 2A
24/12/2020 HepaFat-AI Incorporated into Blackford Analysis
11/12/2020 Secondary Trading Notice & Appendix 2A
09/12/2020 HepaFat-AI gains US FDA clearance
08/12/2020 Trading Halt
08/12/2020 Pause in Trading
27/11/2020 Secondary Trading Notice & Appendix 2A
19/11/2020 Results of Meeting
19/11/2020 Investor Presentation November 2020
26/10/2020 Appendix 4C - quarterly
16/10/2020 Notice of Annual General Meeting/Proxy Form
09/10/2020 Secondary Trading Notice & Appendix 2A
06/10/2020 New Pulmonary Embolism AI Solution Developed
30/09/2020 Appendix 4G and Corporate Governance Statement
30/09/2020 Annual Report to shareholders
10/09/2020 Proposed issue of Securities - RHT
10/09/2020 Execution of Licence Agreement
20/08/2020 Preliminary Final Report
28/07/2020 Appendix 4C - quarterly
26/05/2020 Additional Information on Announcement Dated 25 May 2020
25/05/2020 Resonance Health Files New Provisional Patent
28/04/2020 Appendix 4C - quarterly
06/04/2020 510(k) Application Submission to U.S. FDA
31/03/2020 Market Update
20/03/2020 Secondary Trading Notice & Appendix 2A
19/03/2020 Proposed issue of Securities - RHT
19/03/2020 Controlled Placement Facility
06/03/2020 Secondary Trading Notice & Appendix 2A
21/02/2020 Half Yearly Report and Accounts
04/02/2020 Licencee & Royalty Agreement with 3DR Laboratories
29/01/2020 Appendix 4C - quarterly
13/01/2020 Appendix 3B and Secondary Trading Notice